Molecular targeting of acid ceramidase: Implications to cancer therapy

Youssef Zeidan, Russell W. Jenkins, John B. Korman, Xiang Liu, Lina M. Obeid, James S. Norris, Yusuf A. Hannun

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Increasingly recognized as bioactive molecules, sphingolipids have been studied in a variety of disease models. The impact of sphingolipids on cancer research facilitated the entry of sphingolipid analogues and enzyme modulators into clinical trials. Owing to its ability to regulate two bioactive sphingolipids, ceramide and sphingosine-1-phosphate, acid ceramidase (AC) emerges as an attractive target for drug development within the sphingolipid metabolic pathway. Indeed, there is extensive evidence supporting a pivotal role for AC in lipid metabolism and cancer biology. In this article, we review the current knowledge of the biochemical properties of AC, its relevance to tumor promotion, and its molecular targeting approaches.

Original languageEnglish (US)
Pages (from-to)653-661
Number of pages9
JournalCurrent Drug Targets
Volume9
Issue number8
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Acid Ceramidase
Sphingolipids
Neoplasms
Therapeutics
Ceramides
Metabolic Networks and Pathways
Lipid Metabolism
Modulators
Tumors
Clinical Trials
Molecules
Enzymes
Research
Pharmaceutical Preparations

Keywords

  • Cancer therapy
  • Ceramidase
  • Ceramide
  • Sphingolipids
  • Sphingosine

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Zeidan, Y., Jenkins, R. W., Korman, J. B., Liu, X., Obeid, L. M., Norris, J. S., & Hannun, Y. A. (2008). Molecular targeting of acid ceramidase: Implications to cancer therapy. Current Drug Targets, 9(8), 653-661. https://doi.org/10.2174/138945008785132358

Molecular targeting of acid ceramidase : Implications to cancer therapy. / Zeidan, Youssef; Jenkins, Russell W.; Korman, John B.; Liu, Xiang; Obeid, Lina M.; Norris, James S.; Hannun, Yusuf A.

In: Current Drug Targets, Vol. 9, No. 8, 2008, p. 653-661.

Research output: Contribution to journalArticle

Zeidan, Y, Jenkins, RW, Korman, JB, Liu, X, Obeid, LM, Norris, JS & Hannun, YA 2008, 'Molecular targeting of acid ceramidase: Implications to cancer therapy', Current Drug Targets, vol. 9, no. 8, pp. 653-661. https://doi.org/10.2174/138945008785132358
Zeidan Y, Jenkins RW, Korman JB, Liu X, Obeid LM, Norris JS et al. Molecular targeting of acid ceramidase: Implications to cancer therapy. Current Drug Targets. 2008;9(8):653-661. https://doi.org/10.2174/138945008785132358
Zeidan, Youssef ; Jenkins, Russell W. ; Korman, John B. ; Liu, Xiang ; Obeid, Lina M. ; Norris, James S. ; Hannun, Yusuf A. / Molecular targeting of acid ceramidase : Implications to cancer therapy. In: Current Drug Targets. 2008 ; Vol. 9, No. 8. pp. 653-661.
@article{32ba5b9f82a844b4bb700d61cd54caeb,
title = "Molecular targeting of acid ceramidase: Implications to cancer therapy",
abstract = "Increasingly recognized as bioactive molecules, sphingolipids have been studied in a variety of disease models. The impact of sphingolipids on cancer research facilitated the entry of sphingolipid analogues and enzyme modulators into clinical trials. Owing to its ability to regulate two bioactive sphingolipids, ceramide and sphingosine-1-phosphate, acid ceramidase (AC) emerges as an attractive target for drug development within the sphingolipid metabolic pathway. Indeed, there is extensive evidence supporting a pivotal role for AC in lipid metabolism and cancer biology. In this article, we review the current knowledge of the biochemical properties of AC, its relevance to tumor promotion, and its molecular targeting approaches.",
keywords = "Cancer therapy, Ceramidase, Ceramide, Sphingolipids, Sphingosine",
author = "Youssef Zeidan and Jenkins, {Russell W.} and Korman, {John B.} and Xiang Liu and Obeid, {Lina M.} and Norris, {James S.} and Hannun, {Yusuf A.}",
year = "2008",
doi = "10.2174/138945008785132358",
language = "English (US)",
volume = "9",
pages = "653--661",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Molecular targeting of acid ceramidase

T2 - Implications to cancer therapy

AU - Zeidan, Youssef

AU - Jenkins, Russell W.

AU - Korman, John B.

AU - Liu, Xiang

AU - Obeid, Lina M.

AU - Norris, James S.

AU - Hannun, Yusuf A.

PY - 2008

Y1 - 2008

N2 - Increasingly recognized as bioactive molecules, sphingolipids have been studied in a variety of disease models. The impact of sphingolipids on cancer research facilitated the entry of sphingolipid analogues and enzyme modulators into clinical trials. Owing to its ability to regulate two bioactive sphingolipids, ceramide and sphingosine-1-phosphate, acid ceramidase (AC) emerges as an attractive target for drug development within the sphingolipid metabolic pathway. Indeed, there is extensive evidence supporting a pivotal role for AC in lipid metabolism and cancer biology. In this article, we review the current knowledge of the biochemical properties of AC, its relevance to tumor promotion, and its molecular targeting approaches.

AB - Increasingly recognized as bioactive molecules, sphingolipids have been studied in a variety of disease models. The impact of sphingolipids on cancer research facilitated the entry of sphingolipid analogues and enzyme modulators into clinical trials. Owing to its ability to regulate two bioactive sphingolipids, ceramide and sphingosine-1-phosphate, acid ceramidase (AC) emerges as an attractive target for drug development within the sphingolipid metabolic pathway. Indeed, there is extensive evidence supporting a pivotal role for AC in lipid metabolism and cancer biology. In this article, we review the current knowledge of the biochemical properties of AC, its relevance to tumor promotion, and its molecular targeting approaches.

KW - Cancer therapy

KW - Ceramidase

KW - Ceramide

KW - Sphingolipids

KW - Sphingosine

UR - http://www.scopus.com/inward/record.url?scp=52449089092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52449089092&partnerID=8YFLogxK

U2 - 10.2174/138945008785132358

DO - 10.2174/138945008785132358

M3 - Article

C2 - 18691012

AN - SCOPUS:52449089092

VL - 9

SP - 653

EP - 661

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 8

ER -